|Day Low/High||12.74 / 13.04|
|52 Wk Low/High||6.07 / 13.76|
The market stood its ground and then some today: * A buy program was the last program standing. * The Nasdaq regained strength. Ns over Ss and Rs. * Financials paused (life insurance particularly weak as spin off not well received) - though rallie...
'Buy low and sell high' is easier said than done, but you can fight your fear with TEVA.
Callout: Results and guidance lift markets, dodging D.C. drama.
Negligible gains for the Dow Jones Industrial Average were enough to put it at records.
Jim Cramer analyzes Thursday's market movers.
The stock is getting hit.
Technology might be about to change the healthcare industry forever, or at least according to Teva Pharmaceutical's CEO.
Uber's first quarter loss was less than the $991 million loss reported 3 months ago.
These stocks should be part of a strong first-quarter earnings season.
It will probably take a close above $38 to turn the chart more bullish.
These two large-cap drug giants should be core parts of any well-diversified portfolio.
Wall Street rallies to new records as leftover goodwill from Friday's rally pushes stocks to new heights.
Yes, he's unpredictable, but is that a reason to sell?
Jim Cramer discusses why investors should be cautious after Teva Pharmaceutical's CEO left the company.
The CEO of Teva Pharmaceuticals has left the company, which has faced a series of challenges.
Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.
Two industries should largely be avoided under this administration: pharma and retail.
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.